Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
109 USD | +1.43% | +2.38% | +74.00% |
23/05 | U.S. FDA advisers back approval for Guardant's cancer test | RE |
14/05 | Piper Sandler Adjusts Price Target on Natera to $120 From $110, Maintains Overweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+74.00% | 1.32TCr | |
+17.90% | 8.26TCr | |
-29.45% | 6.99TCr | |
0.00% | 2.65TCr | |
+3.06% | 1.73TCr | |
-12.24% | 1.66TCr | |
+2.48% | 1.56TCr | |
+0.38% | 1.27TCr | |
+73.35% | 1.26TCr | |
+2.74% | 1.22TCr |
- Stock Market
- Equities
- NTRA Stock
- News Natera, Inc.
- Earnings Flash (NTRA) NATERA Reports Q1 Revenue $367.7M, vs. Street Est of $315.3M